Outlook Therapeutics, Inc. last reported quarterly results on Aug 12, 2026, for Q3 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.15. It usually reports 43–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q4 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
—
|
-20
-0.8%
|
-0.15
+72.7%
|
|
May 13, 2026
43 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
—
|
-4
+90.4%
|
-0.05
+96.7%
|
|
Feb 17, 2026
48 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
—
|
-23
-232.7%
|
-0.38
-152.8%
|
|
Aug 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
2
|
-20
-145.4%
|
-0.55
+38.2%
|
|
May 15, 2025
45 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
—
|
-46
+59.4%
|
-1.50
+81.3%
|
|
Feb 14, 2025
45 days after quarter end
|
Q1 FY2025
ended Dec 31, 2024
|
—
|
17
+255.5%
|
0.72
+183.7%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OTLK (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Iselin, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc. (until Nov 13, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.